1. Natural temporal variability in Lp(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx antisense oligonucleotide clinical trials. (September 2016) Authors: Viney, N.J.; Marcovina, S.; Tami, J.; Xia, S.; Witztum, J.L.; Tsimikas, S. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Prevalence of LPA single nucleotide polymorphisms and isoforms in patients enrolled in a phase 2 IONIS-APO(a)Rx clinical trial. (September 2016) Authors: Stroes, E.S.; van der Valk, F.M.; Gaudet, D.; Gouni-Berthold, I.; Riksen, N.P.; Steinhagen-Thiessen, E.; Isermann, B.; Nordestgaard, B.; Viney, N.J.; Marcovina, S.; Hughes, S.G.; Tami, J.; Xia, S.; Witztum, J.L.; Tsimikas, S. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Rationale and design of a clinical trial to assess Lp(a) lowering with ionis-apo(a)-LRX in patients undergoing apheresis for elevated Lp(a) and recurrent cardiovascular events. (September 2016) Authors: Moriarty, P.M.; Thiessen, E.S.; Witztum, J.L.; Viney, N.J.; Tsimikas, S. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗